Dried Blood Spot Methodology in Combination With Liquid Chromatography/Tandem Mass Spectrometry Facilitates the Monitoring of Teriflunomide

BACKGROUND: Teriflunomide, a once-daily oral immunomodulator approved for treatment of relapsing-remitting multiple sclerosis, is eliminated slowly from plasma. If necessary to rapidly lower plasma concentrations of teriflunomide, an accelerated elimination procedure using cholestyramine or activate...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Ther Drug Monit
Autors principals: Filali-Ansary, Aziz, Lunven, Catherine, Turpault, Sandrine, Beyer, Yann-Joel, O'Brien, Amy, Delfolie, Astrid, Boyanova, Neli, Sanderink, Ger-Jan, Baldinetti, Francesca
Format: Artigo
Idioma:Inglês
Publicat: Therapeutic Drug Monitoring 2016
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4949010/
https://ncbi.nlm.nih.gov/pubmed/27015245
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/FTD.0000000000000302
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars